Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China

Abstract

BackgroundTo report the clinical outcomes in Chinese patients with primary open-angle glaucoma and ocular hypertension treated with bimatoprost 0.03% therapy.MethodsTwo hundred sixty-three Chinese patients with primary open-angle glaucoma and ocular hypertension who needed initial or additional intraocular pressure (IOP) lowering were recruited in this prospective, open-label, multicenter clinical study and were treated with bimatoprost 0.03%. Patients received bimatoprost 0.03% as initial, replacement or adjunctive IOP-lowering therapy, and follow-up visits were performed at week 1, and month 1 and 3 of the bimatoprost treatment. The efficacy outcome measure was the post-treatment IOP level. The safety outcome measures included the rate of medication-related symptoms, physical signs, reported adverse events, and the level of conjunctival hyperemia.ResultsAmong 240 patients who could be categorized by pre-existing therapies and the bimatoprost therapy regimen in the study, IOP values observed in all medication conditions showed significant IOP reduction at all study visits compared with baseline. At 3 months, 8.0 ± 3.7 mmHg (32.0%) reduction in IOP was observed in treatment-naive patients after bimatoprost monotherapy; in the patients previously on various therapy regimens, 1.9 ± 2.8 mmHg (9.5%) to 6.4 ± 6.1 mmHg (24.8%) additional IOP lowering was achieved after switching to bimatoprost monotherapy or bimatoprost combination therapy. The most common adverse event was conjunctival hyperemia, mainly of trace and mild intensity.ConclusionsOur results show that bimatoprost 0.03% was effective in lowering IOP with favorable safety in Chinese primary open-angle glaucoma and ocular hypertension patients.

Cost-effectiveness of glaucoma management with monotherapy medications in Egypt

“…This was in consistence with results of some other studies which stated that bimatoprost significantly decrease IOP[ 9 10 11 ] and those which stated that topically applied twice daily for 1 month, brimonidine tartrate 0.2% has clinical effectiveness equivalent to timolol 0.5% in Taiwanese patients with glaucoma. [ 12 ]…”

Fixed-combination treatments for intraocular hypertension in Chinese patients – focus on bimatoprost-timolol

“…In patients who had previously received various therapy regimens, an additional IOP reduction, ranging from 1.9±2.8 mmHg (9.5%) to 6.4±6.1 mmHg (24.8%), was achieved after switching to bimatoprost monotherapy or bimatoprost combination therapy. 28 …”

Bimatoprost loaded nanovesicular long-acting sub-conjunctival in-situ gelling implant: In vitro and in vivo evaluation

“…It is slightly soluble (0.0187 mg/ml), lipophilic (Log P=3.2) molecule, with a large molecular weight (415.56Da). BMT marketed eye drop (0.03%) effectively lower IOP, by 6.5-8.9 mmHg, over long-term use in glaucoma and ocular hypertension (OHT) [8]. A 0.03% bimatoprost, eye drops have been associated with conjunctival congestion probably due to nitric oxide-mediated vasodilatation in the conjunctiva [6], which was reduced significantly when BMT was used at a lower concentration of 0.01% (Lumigan, Allergan, Inc.).…”